Ignite Creation Date:
2024-05-06 @ 3:24 AM
Last Modification Date:
2024-10-26 @ 11:33 AM
Study NCT ID:
NCT02287428
Status:
RECRUITING
Last Update Posted:
2024-05-28
First Post:
2014-10-29
Brief Title:
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-11
Start Date Type:
ACTUAL
Primary Completion Date:
2025-06
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-06
Completion Date Type:
ESTIMATED
First Submit Date:
2014-10-29
First Submit QC Date:
November 6 2014
Study First Post Date:
2014-11-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-24
Last Update Post Date:
2024-05-28
Last Update Post Date Type:
ACTUAL